Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 3 Ultra-high-field MRI at 7.0T (patients 5 and 6)‏

Published byMaja Martinsson Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 3 Ultra-high-field MRI at 7.0T (patients 5 and 6)‏"— Presentation transcript:

1 Figure 3 Ultra-high-field MRI at 7.0T (patients 5 and 6)‏
Ultra-high-field MRI at 7.0T (patients 5 and 6) Supratentorial T2*-weighted (A, B) and postgadolinium T1-weighted images (D) of patient 5 obtained at 7.0T are displayed. Postgadolinium T1-weighted imaging depicts a small contrast-enhancing lesion (black arrow, D) that is only marginally delineated on corresponding T2*-weighted images (zoom, B) despite using a very high spatial resolution of 0.08 mm3. Fusion (C) of coregistered postgadolinium T1-weighted (D) and T2*-weighted (B) identifies a small brain vessel within the center of the chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) lesion (white arrow, C). T2*w = 2D T2*-weighted fast low angle shot at 7.0T, echo time (TE) = 25.0 ms, repetition time (TR) = 1,820 ms, spatial resolution = 0.2 × 0.2 × 2 mm3; T1-gad = postgadolinium 3D T1-weighted magnetization-prepared rapid gradient echo at 7.0T, TE = 2.98 ms, TR = 2,300 ms, inversion time = 900 ms, spatial resolution = 1.0 × 1.0 × 1.0 mm3. Morten Blaabjerg et al. Neurol Neuroimmunol Neuroinflamm 2016;3:e226 © 2016 American Academy of Neurology

Download ppt "Figure 3 Ultra-high-field MRI at 7.0T (patients 5 and 6)‏"

Similar presentations

Figure 2. MRI features of patients with MS who had antibodies to myelin oligodendrocyte glycoprotein MRI features of patients with MS who had antibodies.

Figure 2. MRI features of patients with MS who had antibodies to myelin oligodendrocyte glycoprotein MRI features of patients with MS who had antibodies.
Figure 1 Initial brain imaging (A–C) patient 1; (D–F) patient 2; (G–I) patient 3; (J–L) patient 4; and (M) patient 2. Initial brain imaging (A–C) patient.

Figure 1 Initial brain imaging (A–C) patient 1; (D–F) patient 2; (G–I) patient 3; (J–L) patient 4; and (M) patient 2. Initial brain imaging (A–C) patient.
Figure 3 Brain MRI findings in patients with MOG-Ab Extensive brain lesions with large diameter (A and B), posterior reversible encephalopathy–like lesions.

Figure 3 Brain MRI findings in patients with MOG-Ab Extensive brain lesions with large diameter (A and B), posterior reversible encephalopathy–like lesions.
Figure 1 Box plot of the venous diameter in lesions

Figure 1 Box plot of the venous diameter in lesions
Figure 1 Brain MRI findings in the present case

Figure 1 Brain MRI findings in the present case
Figure 4. Brain imaging and neuropathologic demonstration of Epstein-Barr virus (EBV) encephalitis in patient PT-10 Brain imaging and neuropathologic demonstration.

Figure 4. Brain imaging and neuropathologic demonstration of Epstein-Barr virus (EBV) encephalitis in patient PT-10 Brain imaging and neuropathologic demonstration.
Figure 2 Spinal cord lesions

Figure 2 Spinal cord lesions
Figure 2 Orbital MRI findings One-third of myelin oligodendrocyte glycoprotein antibody–positive patients revealed extensive enhancement patterns that.

Figure 2 Orbital MRI findings One-third of myelin oligodendrocyte glycoprotein antibody–positive patients revealed extensive enhancement patterns that.
Figure Neuroimaging and pathology

Figure Neuroimaging and pathology
Figure 1 Coronal MRI images showing the evolution of white matter abnormality and atrophy of patient 1 Coronal MRI images showing the evolution of white.

Figure 1 Coronal MRI images showing the evolution of white matter abnormality and atrophy of patient 1 Coronal MRI images showing the evolution of white.
Figure Facial photograph during headache attack and brain and upper cervical cord MRI Facial photograph during headache attack and brain and upper cervical.

Figure Facial photograph during headache attack and brain and upper cervical cord MRI Facial photograph during headache attack and brain and upper cervical.
Figure Brain MRI of the patient throughout the disease course(A) Brain MRI at the time of cerebral toxoplasmosis diagnosis (a) and after 1 month of toxoplasmosis.

Figure Brain MRI of the patient throughout the disease course(A) Brain MRI at the time of cerebral toxoplasmosis diagnosis (a) and after 1 month of toxoplasmosis.
Figure 3 Example of venous narrowing

Figure 3 Example of venous narrowing
Figure 1 MRI head in faciobrachial dystonic seizures (A) Axial fluid-attenuated inversion recovery image from patient 3 in table 2 shows T2-weighted hyperintensity.

Figure 1 MRI head in faciobrachial dystonic seizures (A) Axial fluid-attenuated inversion recovery image from patient 3 in table 2 shows T2-weighted hyperintensity.
Figure 1 Histopathologic features of a chronic active and a chronic plaque in the MS brain Histopathologic features of a chronic active and a chronic plaque.

Figure 1 Histopathologic features of a chronic active and a chronic plaque in the MS brain Histopathologic features of a chronic active and a chronic plaque.
Figure Radiographic and histopathologic findings (A) Brain MRI at presentation shows multiple areas of T2 hyperintensity in the mesial temporal lobes,

Figure Radiographic and histopathologic findings (A) Brain MRI at presentation shows multiple areas of T2 hyperintensity in the mesial temporal lobes,
Figure 1. Prebiopsy and postbiopsy MRI

Figure 1. Prebiopsy and postbiopsy MRI
Figure 1. Brain MRI follow-up of Sjögren syndrome–associated type II mixed cryoglobulinemic cerebral vasculitis treated with rituximab Brain MRI follow-up.

Figure 1. Brain MRI follow-up of Sjögren syndrome–associated type II mixed cryoglobulinemic cerebral vasculitis treated with rituximab Brain MRI follow-up.
Figure 3. MRI of compressive optic neuropathy caused by dural lesions in sarcoidosis MRI of compressive optic neuropathy caused by dural lesions in sarcoidosis.

Figure 3. MRI of compressive optic neuropathy caused by dural lesions in sarcoidosis MRI of compressive optic neuropathy caused by dural lesions in sarcoidosis.
Figure Brain MRI and biopsy specimens from the pontine lesion

Figure Brain MRI and biopsy specimens from the pontine lesion

Similar presentations

Ads by Google